Pharmaceutical Executive March 21, 2024
Valder Curran discusses recent developments with the IRA.
Alice Valder Curran, partner at Hogan Lovells, spoke with Pharmaceutical Executive about the industry’s reaction the Inflation Reduction Act (IRA). The act comes with certain price control provisions that have sparked a significant reaction from people across the industry, but negotiations are ongoing and Curran breaks down the current situation.
Pharmaceutical Executive: What has the reaction to the IRA been from the pharma industry?
Alice Valder Curran: Industry’s reaction has evolved in the period since the statute’s passage in August 2022. The price negotiation provisions are incredibly complicated, and so in the early days post-enactment much of the concern was fueled by the unknowns. Industry recognized that the IRA’s price control provisions could...
Today's Sponsors
Today's Sponsor